featured
Dr. Peter Libby on PCSK9 Inhibitors: Where Are We in 2013 on the Management of LDL?
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Effect of an RNA Interference Drug on the Synthesis of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Concentration of Serum LDL Cholesterol in Healthy Volunteers: A Randomised, Single-Blind, Placebo-Controlled, Phase 1 Trial
- AHA 2013: More Late-Breaking Trials—Joerg Herrmann, MD
- Eligibility for Statins Will Increase Based on Guidelines
-
Brown MS, Goldstein JL. Koch's postulates for cholesterol. Cell. 1992;71(2):187-188.
Disclosure statements are available on the authors' profiles: